INTRODUCTION: Gene expression signatures have been identified for epithelial ovarian cancer survival (TCGA) and intrinsic subtypes (Tothill et al.). One obstacle to clinical translation is that these signatures were developed using frozen tissue, whereas usually only formalin-fixed, paraffin embedded (FFPE) tissue is available. The aim of this study was to determine if gene expression signatures can be translated to fixed archival tissues. METHODS: RNA extracted from FFPE sections from 240 primary ovarian cancers was analyzed by DASL on Illumina BeadChip arrays. Concordance of expression at the individual gene level was assessed by comparing array data from the same cancers (30 frozen samples analyzed on Affymetrix arrays versus FFPE DASL). RESULTS: The correlation between FFPE and frozen survival signature estimates was 0.774. The TCGA signature using DASL was predictive of survival in 106 advanced stage high grade serous ovarian cancers (median survival 33 versus 60 months, estimated hazard ratio for death 2.30, P=0.0007). Similar to Tothill, we found using DASL that most high grade serous ovarian cancers (102/110, 93%) were assigned to subtypes 1, 2, 4 and 5, whereas most endometrioid, clear cell, mucinous and low grade serous cases (39/57, 68%) were assigned to subtypes 3 and 6 (P<10e-15). CONCLUSIONS: Although individual probe estimates of microarrays may be weakly correlated between FFPE and frozen samples, combinations of probes have robust ability to predict survival and subtype. This suggests that it may be possible to use these signatures for prognostic and predictive purposes as we seek to individualize the treatment of ovarian cancer.
INTRODUCTION: Gene expression signatures have been identified for epithelial ovarian cancer survival (TCGA) and intrinsic subtypes (Tothill et al.). One obstacle to clinical translation is that these signatures were developed using frozen tissue, whereas usually only formalin-fixed, paraffin embedded (FFPE) tissue is available. The aim of this study was to determine if gene expression signatures can be translated to fixed archival tissues. METHODS: RNA extracted from FFPE sections from 240 primary ovarian cancers was analyzed by DASL on Illumina BeadChip arrays. Concordance of expression at the individual gene level was assessed by comparing array data from the same cancers (30 frozen samples analyzed on Affymetrix arrays versus FFPE DASL). RESULTS: The correlation between FFPE and frozen survival signature estimates was 0.774. The TCGA signature using DASL was predictive of survival in 106 advanced stage high grade serous ovarian cancers (median survival 33 versus 60 months, estimated hazard ratio for death 2.30, P=0.0007). Similar to Tothill, we found using DASL that most high grade serous ovarian cancers (102/110, 93%) were assigned to subtypes 1, 2, 4 and 5, whereas most endometrioid, clear cell, mucinous and low grade serous cases (39/57, 68%) were assigned to subtypes 3 and 6 (P<10e-15). CONCLUSIONS: Although individual probe estimates of microarrays may be weakly correlated between FFPE and frozen samples, combinations of probes have robust ability to predict survival and subtype. This suggests that it may be possible to use these signatures for prognostic and predictive purposes as we seek to individualize the treatment of ovarian cancer.
Authors: Richard D Kennedy; Max Bylesjo; Peter Kerr; Timothy Davison; Julie M Black; Elaine W Kay; Robert J Holt; Vitali Proutski; Miika Ahdesmaki; Vadim Farztdinov; Nicolas Goffard; Peter Hey; Fionnuala McDyer; Karl Mulligan; Julie Mussen; Eamonn O'Brien; Gavin Oliver; Steven M Walker; Jude M Mulligan; Claire Wilson; Andreas Winter; Diarmuid O'Donoghue; Hugh Mulcahy; Jacintha O'Sullivan; Kieran Sheahan; John Hyland; Rajiv Dhir; Oliver F Bathe; Ola Winqvist; Upender Manne; Chandrakumar Shanmugam; Sridhar Ramaswamy; Eduardo J Leon; William I Smith; Ultan McDermott; Richard H Wilson; Daniel Longley; John Marshall; Robert Cummins; Daniel J Sargent; Patrick G Johnston; D Paul Harkin Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Dimitrios Spentzos; Douglas A Levine; Marco F Ramoni; Marie Joseph; Xuesong Gu; Jeff Boyd; Towia A Libermann; Stephen A Cannistra Journal: J Clin Oncol Date: 2004-10-25 Impact factor: 44.544
Authors: Dimitrios Spentzos; Douglas A Levine; Shakirahmed Kolia; Hasan Otu; Jeff Boyd; Towia A Libermann; Stephen A Cannistra Journal: J Clin Oncol Date: 2005-10-03 Impact factor: 44.544
Authors: V Shridhar; J Lee; A Pandita; S Iturria; R Avula; J Staub; M Morrissey; E Calhoun; A Sen; K Kalli; G Keeney; P Roche; W Cliby; K Lu; R Schmandt; G B Mills; R C Bast; C D James; F J Couch; L C Hartmann; J Lillie; D I Smith Journal: Cancer Res Date: 2001-08-01 Impact factor: 12.701
Authors: Tomas Bonome; Ji-Young Lee; Dong-Choon Park; Mike Radonovich; Cindy Pise-Masison; John Brady; Ginger J Gardner; Ke Hao; Wing H Wong; J Carl Barrett; Karen H Lu; Anil K Sood; David M Gershenson; Samuel C Mok; Michael J Birrer Journal: Cancer Res Date: 2005-11-15 Impact factor: 12.701
Authors: Michael F Press; Guido Sauter; Leslie Bernstein; Ivonne E Villalobos; Martina Mirlacher; Jian-Yuan Zhou; Rooba Wardeh; Yong-Tian Li; Roberta Guzman; Yanling Ma; Jane Sullivan-Halley; Angela Santiago; Jinha M Park; Alessandro Riva; Dennis J Slamon Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: Andrew Berchuck; Edwin S Iversen; Johnathan M Lancaster; Jennifer Pittman; Jingqin Luo; Paula Lee; Susan Murphy; Holly K Dressman; Phillip G Febbo; Mike West; Joseph R Nevins; Jeffrey R Marks Journal: Clin Cancer Res Date: 2005-05-15 Impact factor: 12.531
Authors: Richard W Tothill; Anna V Tinker; Joshy George; Robert Brown; Stephen B Fox; Stephen Lade; Daryl S Johnson; Melanie K Trivett; Dariush Etemadmoghadam; Bianca Locandro; Nadia Traficante; Sian Fereday; Jillian A Hung; Yoke-Eng Chiew; Izhak Haviv; Dorota Gertig; Anna DeFazio; David D L Bowtell Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531
Authors: Tomas Bonome; Douglas A Levine; Joanna Shih; Mike Randonovich; Cindy A Pise-Masison; Faina Bogomolniy; Laurent Ozbun; John Brady; J Carl Barrett; Jeff Boyd; Michael J Birrer Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Raphael Pelossof; Oliver S Chow; Lauren Fairchild; J Joshua Smith; Manu Setty; Chin-Tung Chen; Zhenbin Chen; Fumiko Egawa; Karin Avila; Christina S Leslie; Julio Garcia-Aguilar Journal: Genes Chromosomes Cancer Date: 2016-04 Impact factor: 5.006
Authors: Stefan Kommoss; Boris Winterhoff; Ann L Oberg; Gottfried E Konecny; Chen Wang; Shaun M Riska; Jian-Bing Fan; Matthew J Maurer; Craig April; Viji Shridhar; Friedrich Kommoss; Andreas du Bois; Felix Hilpert; Sven Mahner; Klaus Baumann; Willibald Schroeder; Alexander Burges; Ulrich Canzler; Jeremy Chien; Andrew C Embleton; Mahesh Parmar; Richard Kaplan; Timothy Perren; Lynn C Hartmann; Ellen L Goode; Sean C Dowdy; Jacobus Pfisterer Journal: Clin Cancer Res Date: 2017-02-03 Impact factor: 12.531
Authors: Joellen M Schildkraut; Edwin S Iversen; Lucy Akushevich; Regina Whitaker; Rex C Bentley; Andrew Berchuck; Jeffrey R Marks Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-08-05 Impact factor: 4.254
Authors: Felipe Vaca-Paniagua; Rosa María Alvarez-Gomez; Hector Aquiles Maldonado-Martínez; Carlos Pérez-Plasencia; Veronica Fragoso-Ontiveros; Federico Lasa-Gonsebatt; Luis Alonso Herrera; David Cantú; Enrique Bargallo-Rocha; Alejandro Mohar; Geoffroy Durand; Nathalie Forey; Catherine Voegele; Maxime Vallée; Florence Le Calvez-Kelm; James McKay; Maude Ardin; Stéphanie Villar; Jiri Zavadil; Magali Olivier Journal: PLoS One Date: 2015-05-11 Impact factor: 3.240
Authors: Heather D Kissel; Thomas G Paulson; Karen Liu; Xiaohong Li; Elizabeth Swisher; Rochelle Garcia; Carissa A Sanchez; Brian J Reid; Susan D Reed; Jennifer Anne Doherty Journal: Obstet Gynecol Int Date: 2013-10-26